Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

/PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, released interim results today...

Related Keywords

Canada ,Maryland ,United States ,Ohio ,Australia ,Cincinnati ,Australian ,Alphyn Biologics ,Neal Koller ,World Dermatology Congress ,Investigator Global Assessment ,Eczema Area ,Severity Index ,Skin Infection Rating Scale ,Treatment Emergent Adverse Event ,Dermatology Congress ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,